Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 4;12:1919. doi: 10.1038/s41598-022-05179-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

The effects of antiepileptic drugs on resting-state EEG oscillations. Grand-averaged power spectrums calculated on the average of all channels are reported before (pre, blue) and after (post, red) the intake of Lamotrigine (a), Levetiracetam (b) and XEN1101 (c). For each drug condition, significant differences are indicated with the respective topographical distribution of t-values where significant channels are indicated with asterisks. Lamotrigine (a) decreases theta power (p = 0.03); Levetiracetam (b) increases theta (p = 0.03), beta (p < 0.001) and gamma (p = 0.001) power; XEN1101 increases delta (p < 0.001), theta (p = 0.01), beta (p = 0.005) and gamma (p = 0.02) power. The significant modulation of beta and gamma power are shown for each drug in a zoomed power spectrum (panels on the right; averaged over significant channels for Levetiracetam and XEN1101, respectively).